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ABSTRACT
Early release of tumor necrosis factor-alpha (TNF-α) during radiotherapy of 
thoracic cancers plays an important role in radiation pneumonitis, whose inhibition 
may provide lung radioprotection. We previously reported radiation inactivates 
Tristetraprolin (TTP), a negative regulator of TNF-α synthesis, which correlated with 
increased TNF-α release. However, the molecular events involved in radiation-induced 
TTP inactivation remain unclear. To determine if eliminating Ttp in mice resulted in a 
phenotypic response to radiation, Ttp-null mice lungs were exposed to a single dose 
of 15 Gy, and TNF-α release and lung inflammation were analyzed at different time 
points post-irradiation. Ttp-/- mice with elevated (9.5±0.6 fold) basal TNF-α showed 
further increase (12.2±0.9 fold, p<0.02) in TNF-α release and acute lung inflammation 
within a week post-irradiation. Further studies using mouse lung macrophage (MH-
S), human lung fibroblast (MRC-5), and exogenous human TTP overexpressing U2OS 
and HEK293 cells upon irradiation (a single dose of 4 Gy) promoted p38-mediated TTP 
phosphorylation at the serine 186 position, which primed it to be recognized by an 
ubiquitin ligase (E3), beta transducing repeat containing protein (β-TrCP), to promote 
polyubiquitination-mediated proteasomal degradation. Consequently, a serine 186 to 
alanine (SA) mutant of TTP was resistant to radiation-induced degradation. Similarly, 
either a p38 kinase inhibitor (SB203580), or siRNA-mediated β-TrCP knockdown, or 
overexpression of dominant negative Cullin1 mutants protected TTP from radiation-
induced degradation. Consequently, SB203580 pretreatment blocked radiation-induced 
TNF-α release and radioprotected macrophages. Together, these data establish the 
involvement of the p38-βTrCP-TTP-TNFα signaling axis in radiation-induced lung 
inflammation and identified p38 inhibition as a possible lung radioprotection strategy.
INTRODUCTION
The efficacy of radiation therapy for upper thoracic 
cancers is limited by radiation pneumonitis. Amifostine, 
a free-radical scavenger and the only FDA-approved 
radioprotector, does not protect lung and carries its own 
substantial toxicity [1-3]. Thus, there is a need to develop 
a lung radioprotector. Various pro-inflammatory cytokines 
including IL-1β, IL-6, and TGF-β1 have been implicated 
in radiation-induced lung toxicity [4-6]. Besides, early 
release of tumor necrosis factor-alpha (TNF-α) is a 
critical factor [7, 8], and we have shown that blocking 
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TNF-α signaling either via knockdown or using antisense 
oligonucleotides against the TNF receptor can protect 
mouse lung from radiation injury [9]. As long-term delivery 
of siRNA or antisense oligonucleotides remains a challenge, 
identification of novel targets that can be accessed using a 
small molecule would be important to limit RILT.
We previously identified an RNA binding anti-
inflammatory protein, Tristetraprolin (TTP) as a major 
negative regulator of radiation-induced TNF-α synthesis by 
mouse lung macrophages [10]. We found radiation promotes 
TTP inactivation via phosphorylation and proteasomal 
degradation, which correlates with increased TNF-α synthesis 
and release. Thus, radiation therapy uses a relatively similar 
mechanism as LPS to cause TTP inactivation leading 
to enhanced TNF-α production [11, 12]. Initial studies 
utilizing different genetically modified mouse models have 
identified p38α-MK2 pathway as a major modulator of 
various inflammatory responses and cytokine production 
including LPS and TNF-α mediated inflammation [13, 14]. 
Similarly, such signaling has been directly linked to various 
inflammatory diseases including rheumatoid arthritis, 
multiple sclerosis, atherosclerosis and chronic obstructive 
pulmonary disease (COPD) [15-18]. Thus, p38 inhibitors are 
being tested in several clinical trials for anti-inflammatory 
efficacy. However, the involvement of p38 kinase activity in 
radiation-induced lung inflammation remains unclear, as does 
the impact of a p38 kinase inhibitor as a radioprotector.
Given the potential relationship between p38 kinase 
and TTP, we decided to obtain a better understanding of the 
physiological relevance of TTP inactivation in developing 
radiation pneumonitis and further identify molecular 
regulators of radiation-induced TTP inactivation and 
degradation. Specific phosphorylation of TTP at serine 
186 by p38 MAPK inactivates its mRNA-destabilizing 
ability [19]. We also found that radiation-induces activation 
of p38 leading to phosphorylation of TTP at Ser186 [10]. 
While analyzing the amino acid sequence, we further noted 
that upon phosphorylation of Ser186
,
 surrounding residues 
(186SPFSGLPS192) can potentially serve as a recognition 
motif (phospho-degron) for an F-box family ubiquitin ligase 
(E3), SCFβ-TrCP(consensus DpSGxxpS, where x could be any 
amino acid) [20, 21]. As β-TrCP is known to be activated by 
radiation, which can induce degradation of certain proteins 
[22], we, therefore, wished to test the hypothesis that p38 
MAP kinase inhibition could provide lung radioprotection 
via blocking radiation-induced Ttp phosphorylation and 
ubiquitination-dependent protein degradation.
In the present study, we used Ttp knockout mice to 
establish the physiological relevance of Ttp in radiation-
induced lung inflammation. Furthermore, we provide 
evidence of a linkage between radiation-induced p38-
mediated TTP phosphorylation and SCFβ-TrCP-mediated 
polyubiquitination and degradation, which in coordination 
promote TTP inactivation allowing a TNF-α mediated 
lung inflammatory response. Using a pan p38 inhibitor, 
we then found inhibition of p38 to be radioprotective.
RESULTS
Ttp knockout mice are susceptible to radiation-
induced pneumonitis
We began our studies by irradiating both the lungs 
of either Ttp+/+ or Ttp-/- mice (C57BL/6 background) with 
a single 15 Gy dose. These mice were observed for a 
month (n=6 per group) after irradiation. While analyzing 
TNF-α levels we noted the basal level of TNF-α to be 
higher (9.54±0.67 fold, p<0.0001) in bronchoalveolar 
lavage (BAL) of Ttp-/- as compared to Ttp+/+ mice (Figure 
1A), which is consistent with a previous report [23]. 
Consequently, histopathological examination of sham-
irradiated Ttp-/- mice lungs showed multi-focal chronic 
inflammation at the alveolar lumens and interstitial 
spaces with occasional focal septal thickening compared 
to sham-irradiated Ttp+/+ mice. An increased number 
of macrophages was also noted in the alveolar lumen 
in the knockout lung (Figure 1B, upper panel). Further, 
upon 15 Gy single dose irradiation, a measurable 
increase (12.2±0.85 fold, p<0.02) in TNF-α levels were 
noted in Ttp-/- mice (n=6 per group) within 12-24 hours 
post-irradiation, which started decreasing by 48 hours 
(10.2±0.85 fold, p=0.15) (Figure 1A). In irradiated Ttp-
/- mice, acute lung tissue damage became evident within 
a week showing focal acute and chronic inflammation in 
the alveolar lumen with very severe and acute chronic 
inflammation in the interstitial spaces (Figure 1B, lower 
panel). In contrast, at the same time point, the irradiated 
wild-type mice showed a minimal increase in focal 
macrophages in the alveolar lumen with marginal changes 
in interstitial inflammation (Figure 1B, lower panel). 
Detailed pathological analyses revealed normal alveolar 
epithelium, vessels and pleura in all animals and there 
was no sign of bronchiolar epithelium damage. Lung 
specimens collected and analyzed for histopathology 
at 1, 2, and 4 weeks post-irradiation (n=6/time point) 
showed persistent inflammation in Ttp-/- mice during this 
observation period, as summarized in Figure 1C. From 
these data, we conclude that Ttp is a negative regulator of 
radiation-induced lung inflammation in mice.
Mouse strains are known to respond differently 
to ionizing radiation; C3H mice are prone to radiation-
induced inflammation, whereas, C57BL/6 mice are 
fibrosis prone [24, 25]. The Ttp-/- mice used in the study 
were in a C57BL/6 background and despite their C57BL/6 
background showed acute inflammation in response to 
radiation thus raising the possibility of Ttp as an important 
determinant. To examine whether ionizing radiation has 
any differential impacts on Ttp levels in different strains 
of mice, C57BL/6 and C3H mice upper thoraxes were 
irradiated with a single dose of 15 Gy. As shown in 
Figure 1D and quantified in Figure 1E, a faster decay of 
Ttp proteins were noted in C3H mice within 4 days of 
irradiation.
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Figure 1: Ttp knockout mice are susceptible to radiation-induced lung inflammation. (A) Fold change in TNF-α in BAL 
either from sham-irradiated (control) or 15 Gy single exposure of Ttp-/- mice compared to Ttp+/+ after indicated times post-irradiation (n=6 
mice for each time point for each genotype category). (B) The thoraxes of Ttp+/+ or Ttp-/- mice were either sham-irradiated (- RT) or exposed 
to 15 Gy. Shown is representative H&E staining of paraffin-embedded lung sections. Scale bar, 200 μm. (C) Summary of histopathological 
observation in Ttp+/+ and Ttp-/- mice upon 15 Gy whole thorax irradiation (n=5 mice for each time point for each genotype category). (D) 
C57BL/6 and C3H mice strains were either sham-irradiated or 15 Gy single exposure of upper thorax. Lung specimens were collected after 
2, 24 and 96 hours post-irradiation and cryo-preserved. Following completion of the study, cryosections were subjected to protein isolation 
as described in the materials and methods and subjected to immunoblotting for total Ttp protein. GAPDH was used as loading control. (E) 
Average band intensity (arbitrary units) was calculated from two representative samples from each group (as shown in panel D) using Image 
J software and plotted against time post-irradiation.
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SCFβ-TrCP is the ubiquitin ligase involved in 
radiation-induced TTP degradation
As Ttp knockout mice were found to be sensitive 
to radiation pneumonitis, and as we previously reported 
that radiation causes TTP protein inactivation primarily 
via enhanced inhibitory phosphorylation as well as via 
inducing protein degradation [10], we next focused our 
studies on improving the mechanistic understanding 
of TTP degradation machinery. To ascertain whether 
radiation-induced TTP protein degradation is mediated 
via ubiquitination-mediated proteasomal degradation, 
we utilized both overexpression and endogenous 
systems. We previously reported that in a mouse 
lung macrophage cell line (MH-S), radiation-induced 
Ttp protein down-regulation can be blocked using 
a proteasome inhibitor MG132 [10]. Here we have 
obtained similar data using U2OS cells overexpressing 
human TTP protein (Figure 2A). Furthermore, a 
concomitant increase in TTP polyubiquitination was 
noted in the presence of MG132 in both the systems 
when TTP was immunoprecipitated using a specific 
antibody (Figure 2B, left panel). Similar data were 
obtained in normal human lung fibroblasts (MRC-5) 
(Figure 2B, right panel). Together, these data show 
that radiation induces polyubiquitination-mediated 
proteasomal degradation of TTP.
To identify the ubiquitin ligase (E3) responsible 
for radiation-induced TTP ubiquitination, we looked for 
the presence of a degron (degradation signal) present in 
TTP protein, which can be recognized by an E3 enzyme. 
Among various E3s, an F-box family ligase, beta 
transducing repeat containing protein (β-TrCP), is known 
to recognize a phospho-degron consisting of the DSpGxxSp 
motif, where ‘x’ could be any amino acid, and serine (S), 
when phosphorylated (P), becomes a recognition motif 
[20, 21]. Additionally, β-TrCP family E3 ligases are 
known to be activated by radiation to degrade proteins 
including CDC25A [22]. While analyzing the TTP primary 
amino acid sequence we identified two probable phospho 
degrons (Figure 3A). ‘Degron I’ spans the N-terminal 
part between amino acids 34-39, and the ‘degron II’ 
spans between amino acids 186-193. To ascertain the 
role of β-TrCP in radiation-induced TTP ubiquitination, 
we used β-TrCP1 specific siRNA and transfected MH-S 
cells with different concentrations of siRNA. As shown 
in Figure 3B, a dose-dependent decrease in β-TrCP1 
levels resulted in a corresponding increase in TTP protein. 
We found similar responses in other cell lines including 
human osteosarcoma U2OS, human lung adenocarcinoma 
A549 and even in human embryonic kidney HEK293 
cells overexpressing human TTP cDNA (Figure 3C). To 
further understand the involvements of β-TrCP1 and its 
homolog β-TrCP2, we utilized HEK293 cells transiently 
Figure 2: Ionizing radiation induces polyubiquitination-mediated proteasomal degradation of TTP. (A) U2OS cells 
overexpressing human TTP were sham irradiated or exposed to 4 Gy and were either left untreated for the next 24 h or treated with 2 μM MG132 
for the last 4 h. Cell lysates were subjected to immunoprecipitation using TTP antibody followed by immunoblotting using ubiquitin (Ub) antibody. 
(B) MH-S (left panel) and MRC-5 (right panel) cells were irradiated as above. Cells were then either left untreated or 6 h after irradiation treated 
with 2 μM MG132 for the next 4 hours. Cell lysates were then subjected to immunoprecipitation and immunoblotting using indicated antibodies.
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Figure 3: SCFβ-TrCP is the ubiquitin ligase involved in radiation-induced TTP degradation. (A) Amino acid sequence 
alignment between human, mouse and rat TTP showing the presence of two putative β-TrCP recognition motifs (degron I and degron 
II). (B) MH-S cells were transfected either with a control or with two different concentrations (10 and 25 nM) of β-TrCP1 siRNA. Forty 
eight hours post-transfection cell lysates were subjected to immunoblotting. Fold changes in TTP and β-TrCP1 were calculated based on 
band intensity using Image J software. (C) U2OS and A549 cells with endogenous TTP or HEK293 cells overexpressing human TTP were 
transfected either with control or β-TrCP1 siRNA. Cell lysates were prepared 48 h post-transfection and immunoblotted. (D) HEK293 
cells overexpressing human TTP in the presence or absence of either β-TrCP1 or β-TrCP2 overexpression as indicated were either sham 
irradiated or irradiated with 4 Gy. Six hours later cells were treated with MG132 as above. Cell lysates were then immunoprecipitated 
using TTP antibody and immunoblotted. (E) U2OS cells were transfected either with control or β-TrCP1 siRNA and 24 h post-transfection 
were either sham-irradiated or irradiated with 4 Gy. Twenty four hours post-irradiation, cell lysates were immunoblotted. Changes in total 
TTP levels were calculated assuming control siRNA treated sample band intensity as 1. (F) U2OS cells overexpressing human TTP were 
co-transfected with various Cullin-1 mutants [either K720R or a Δ (1-327) mutant] as indicated. Cells were irradiated as above, and 24 
h post-irradiation, cell lysates were immunoblotted. Changes in total TTP levels were calculated assuming TTP overexpressed untreated 
control band intensity as 1.
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overexpressing human TTP in the presence or absence 
of either β-TrCP1 or β-TrCP2. In sham-irradiated cells, 
TTP immunoprecipitation followed by immunoblotting 
using either ubiquitin (Ub) or DDK (tag used to detect 
both b-TrCP1 and 2) antibodies showed minimal changes 
in TTP ubiquitination and no detectable interactions 
between TTP and β-TrCP1/2-DDK (Figure 3D, lanes 
1-3). However, there was a significant increase in 
TTP interaction with β-TrCP1/2, which resulted in the 
increase of TTP polyubiquitination within 6 hours of 4 
Gy exposure (Figure 3D, lanes 4-6). Similarly, a pooled 
siRNA-mediated knockdown of β-TrCP protected 
radiation-induced TTP downregulation (Figure 3E). 
As Cullin plays an important role in β-TrCP mediated 
substrate polyubiquitination and degradation, we tested 
two different Cullin-1 mutants (K720R and 1-327 
deletion), which are known to inhibit β-TrCP activity 
[26]. In Figure 3F, we demonstrate that radiation-induced 
TTP downregulation can be inhibited by overexpressing 
either of the two Cullin-1 mutants. We, therefore, conclude 
that upon irradiation, TTP is recognized by β-TrCP via 
phospho-degron(s) leading to ubiquitination-mediated 
proteasomal degradation.
To further understand the importance of the two 
probable degrons in radiation-induced TTP degradation, 
we carried out site-directed mutagenesis at both degrons 
(I and II). As shown in Figure 4A (left panel), serine 
(S) to alanine (A) substitution (SA) at degron I had a 
minimal effect on radiation-induced TTP downregulation. 
In contrast, a mutation of S186A provided significant 
protection of radiation-induced decay (Figure 4A, right 
panel). Similarly, the TTP (S186A) mutant showed 
minimal change in radiation-induced polyubiquitination 
(Figure 4B, compare lanes 2, 4 and 6). Thus, degron 
II of TTP appears to be primarily responsible for 
substrate recognition by β-TrCP for radiation-induced 
polyubiquitination and degradation. In our previous study 
[10] (Figure 2E) we reported that overexpression of S186A 
mutant TTP can block radiation-induced TNF-α release 
by irradiated lung macrophages (MH-S), suggesting the 
functional significance of this phosphorylation.
Radiation-induced p38-mediated Ser186 
phosphorylation of TTP primes it for 
degradation
Previous studies have reported that p38-mediated 
serine 186 phosphorylation promotes functional 
inactivation of TTP, which is essential for increased 
stabilization of various cytokine transcripts including 
TNF-α [12, 27, 28]. As we showed previously that 
radiation induces p38-mediated TTP phosphorylation 
at S186 both in vitro and in vivo, and as now we have 
found that S186A mutant TTP is resistant to radiation-
induced ubiquitination and degradation, we hypothesized 
that, in the context of radiation the S186 phosphorylation 
and β-TrCP mediated ubiquitination and degradation 
are interconnected. To further establish radiation effects 
on S186 phosphorylation of TTP, we utilized a U2OS 
overexpression system expressing wild-type human 
TTP. Cells were exposed to 4 Gy, and cell lysates were 
immunoprecipitated using TTP antibody and subjected 
to mass spectrometry analyses. As shown in Figure 4C, 
we could detect an S186 phosphorylated fragment only 
in the irradiated sample, supporting the previous 
observation. Taken together, these data show that radiation 
induces Ser186 phosphorylation of TTP to prime it for 
β-TrCP recognition followed by polyubiquitination and 
proteasomal degradation.
P38 inhibitor (SB203580) provides 
radioprotection of cytokine producing 
macrophages, but not for lung cancer cells
Previously, we have shown SB203580 pretreatment 
can inhibit radiation-induced TTP phosphorylation and 
TNF-α secretion by MH-S cells [10]. Similarly, U2OS 
cells overexpressing human TTP when treated with 
the SB compound prior to radiation, also blocked TTP 
degradation (Figure 5A). As the addition of TNF-α is 
known to radiosensitize cells [29, 30], we, therefore, 
considered the possibility that a p38 inhibitor could 
radioprotect lung macrophages by blocking TNF-α 
release. To test our hypothesis, we pretreated mouse 
lung macrophage cells (MH-S) plated at clonal density 
with SB203580 thirty minutes prior to different doses of 
radiation and assessed colony formation ability. As shown 
in Figure 5B, an improved survival of macrophages 
was noted when they were irradiated in the presence of 
SB203580, with a radiation enhancement ratio (ER) of 
0.86. Importantly, similar pretreatment of SB203580 
using human lung adenocarcinoma cells (H441) did not 
provide any radioprotection (ER 1.03) (Figure 5C). Thus, 
we identified a novel radioprotective effect of SB203580 
specific to cytokine producing lung macrophages with no 
effects on lung cancer cells.
DISCUSSION
Previously, we have identified Tristetraprolin 
(TTP) as a negative regulator of radiation-induced 
TNF-α production by mouse lung macrophages [10]. 
Here, we report that upon genetic ablation of Ttp, 
mouse lungs were more susceptible to radiation-induced 
inflammation (pneumonitis), which is correlated with 
increased TNF-α levels. These findings suggest that Ttp 
may be a ‘negative’ regulator of radiation-induced lung 
inflammation in mice, primarily via controlling the early 
release of TNF-α. Previously [10], we have identified 
two primary ways ionizing irradiation can inactivate 
TTP: (i) via p38-mediated inhibitory phosphorylation 
and (ii) via proteasome-mediated degradation. Here, we 
Oncotarget47773www.impactjournals.com/oncotarget
have identified a linkage between the two processes; 
mass spectrometry showed that radiation causes TTP 
phosphorylation at serine186 (a known p38-mediated 
phosphorylation site), which is then recognized by 
SCFβ-TrCP E3 ligase to promote polyubiquitination and 
proteasomal degradation. Such concerted phosphorylation 
and degradation-mediated inactivation of TTP releases its 
anti-inflammatory effects, allowing the secretion of TNF-α 
by irradiated lung macrophages. A schematic model 
summarizing our findings is shown in Figure 5D.
As reported previously, Ttp knockout mice secrete 
higher levels of various pro-inflammatory cytokines, 
particularly TNF-α, resulting in inflammatory responses 
in tissues including arthritis, which can be mitigated by 
Figure 4: Radiation-induced Ser186 phosphorylation of TTP primes it for polyubiquitination. (A) U2OS cells overexpressing 
either wild-type (WT) or various serine to alanine mutants [S34A, S34/35/39A (3SA) and S186A] of human TTP, were either sham 
irradiated or treated with 4 Gy. Twenty-four hours post-irradiation cell lysates were immunoblotted. Changes in total TTP levels were 
calculated assuming TTP overexpressed untreated control band intensity as 1. (B) U2OS cells overexpressing either WT or various (3SA 
and S186A) mutants of TTP were either sham-irradiated or treated with 4 Gy. Six hours after irradiation cells were treated with MG132 as 
above, and 4 h post-MG132 treatment cell lysates were immunoprecipitated using TTP antibody and immunoblotted. (C) Representative 
MS/MS spectrum identifying serine186 phosphorylation on TTP upon 4 Gy.
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injecting anti-TNF-α neutralizing antibody [23]. In this 
manuscript, we report for the first time that Ttp knockout 
mice are also prone to radiation-induced lung inflammation. 
Radiation pneumonitis is reported to be mouse strain-
dependent; C3H-HeN mice are more prone to radiation 
pneumonitis, whereas, C57BL/6 mice are not [24, 31]. 
Importantly, the Ttp-/- mice used in this study had a C57BL/6 
background. After giving 15 Gy to the whole-lung, we noted 
Figure 5: P38 inhibitor (SB203580) blocks radiation-induced TTP degradation and radioprotects lung macrophages. 
(A) U2OS cells overexpressing human TTP were either treated with DMSO or 1 μM SB203580 thirty minutes prior to 4 Gy. Twenty-
four hours after irradiation cell lysates were prepared and immunoblotted. Change in total TTP levels were calculated assuming TTP 
overexpressed untreated control band intensity as 1. (B, C) Either MH-S cells (in B) or H441 cells (in C) were plated at clonal density and 
after 24 h treated with 1 μM of SB203580 thirty minutes prior to different doses of radiation. Cells were then left for colony formation 
as described in materials and methods. (D) Schematic model showing the interconnectedness between p38-mediated phosphorylation 
and SCFβ-TrCP-mediated degradation in radiation-induced TTP inactivation and further proposing the novel use of the p38 inhibitor as a 
lung radioprotector. Previously reported observations are shown using solid blue lines, whereas, data shown in the current manuscript are 
denoted using solid green lines.
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acute lung inflammation within a week which was sustained 
for at least during the observation period of 4 weeks. In 
a recent study using C57BL/6 and C3H strains, it was 
demonstrated that radiation exposure can cause differential 
elevation of alveolar and interstitial macrophages at different 
time points, which may be responsible for differential 
outcomes [32]. However, no molecular insight has been 
provided for such differential macrophage activation. Our 
in vivo findings raised the possibility that Ttp plays an 
important role in blocking early phenotypes of radiation-
induced lung pneumonitis in the C57BL/6 as compared 
to the C3H-HeN strain. Our data (Figure 1D, 1E) further 
support such a hypothesis, where we noted faster decay 
of Ttp protein particularly in C3H mice. However, we 
acknowledge that the use of a single strain, rather than 
multiple strains, is a limitation of our study.
The possibility of TTP’s involvement as a predictor 
of radiation pneumonitis emphasized our rationale to 
identify molecular regulators controlling the levels of 
TTP proteins. TTP protein is inherently unstable and 
undergoes proteasomal degradation upon radiation 
[10]. However, regulators including the ubiquitination 
machinery involved in maintaining lower TTP protein 
steady state levels in cells remain unclear. Previous 
studies have shown that, following TNF-α treatment, 
Tumor Necrosis Factor Receptor-associated Factor 2 
(TRAF-2), an ubiquitin ligase (E3), is responsible for 
K63-linked polyubiquitination of TTP [33]. However, 
such ‘hypermodification’ of TTP seems to work as a 
non-degrading signal and is important in balancing 
the activation of NF-κB and JNK signaling cascades to 
determine cell fate. In another study, a member of the 
Cullin family (Cullin-4B), a known component of the 
CRL4 ubiquitin ligase complex, was found to interact with 
TTP upon LPS stimulation. Such association was reported 
to be critical for the TTP-TNF-α mRNA ribonucleoprotein 
(mRNP) complex loading onto polysomes, which in turn 
prevents decay of TNF-α mRNA [34]. In fact, unlike 
radiation (which downregulates TTP), LPS treatment is 
known to upregulate TTP phosphorylation (functionally 
inactive) as well as protein steady state levels [35, 36] and 
may be mediated via the above mechanism. In comparison, 
our findings of radiation-induced TTP protein degradation 
is unique and the identification of β-TrCP as an ubiquitin 
ligase is novel. Interestingly, a previous study has shown 
that LPS treatment can mitigate radiation-induced lung 
injury in knockout mice of either TNF-α or its receptors 
in the C57BL/6J background [37]. Thus, one could 
speculate that LPS-induced compensatory upregulation of 
functionally inactive (phosphorylated) Ttp can still inhibit 
radiation-induced lung inflammation, although this needs 
to be tested.
Our study further expands the role of β-TrCP in 
inflammation and cytokine responses. For example, the 
role of β-TrCP in the degradation of IκBα leading to 
the activation of an inflammatory transcription factor, 
NF-κB [38] is well established. Upon LPS treatment, 
β-TrCP promotes inflammation via polyubiquitination 
and degradation of an anti-inflammatory protein, called 
lysophosphatidylcholine acyltransferase 1 (LPCAT1) 
[39]. Similarly, in IL-17-mediated inflammation, 
β-TrCP degrades Act1, an adaptor protein associated 
with IL-17 receptor desensitization [40]. During TNF-α 
induced inflammation, β-TrCP1 promotes such activity 
via degrading an anti-inflammatory protein, silencing 
mediator of retinoic acid and thyroid hormone receptor 
(SMRT) [41]. Recently, β-TrCP was also implicated in 
inflammatory cytokine production via polyubiquitination 
and degradation of AUF1 [42], another ARE-binding 
cytokine mRNA decay factor, similar to TTP. We have 
previously demonstrated the downregulation of the 
anti-inflammatory TTP protein when mouse lungs were 
irradiated with a single dose of 15 Gy [10]. Here, using 
various cell biology and biochemical analyses, we have 
established the involvement of β-TrCP in radiation-
induced TTP degradation that in turn promotes increased 
TNF-α release and lung inflammation.
The part of our study that is most clinically relevant 
is the identification of p38 as the kinase responsible 
for radiation-induced phosphorylation of TTP at 
serine 186 leading to functional inactivation as well as 
facilitation of β-TrCP-mediated polyubiquitination, and 
degradation, which allows stabilization of the TNF-α 
transcript. Such findings led us to hypothesize that a p38 
inhibitor might protect TTP from radiation-induced post-
translational modifications including phosphorylation and 
ubiquitination, thus could be used as a lung radioprotector. 
Our proof-of-principle study with a pan-p38 inhibitor 
(SB203580) supports such a hypothesis. Unfortunately, 
SB203580 cannot be tested as a lung radioprotector due to 
poor pharmacokinetics properties.
In conclusion, by utilizing Ttp-/- mice we 
demonstrated the in vivo anti-inflammatory role of Ttp in 
radiation pneumonitis. Our data identify p38 as a regulator 
of radiation-induced TTP inactivation and provide in vitro 
evidence that a pharmacologically favorable p38 inhibitor 
may warrant testing as a lung radioprotector in future 
preclinical and clinical studies.
MATERIALS AND METHODS
Ethics statement
Here we confirm that all the animal studies 
conducted here were approved by the University 
Committee on Use and Care of Animals (UCUCA) of the 
University of Michigan (protocol # PRO00005911).
Cells and reagents
The mouse alveolar macrophage cell line MH-S, and 
human lung fibroblast MRC-5 cells were obtained from 
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ATCC and cultured in regular DMEM supplemented with 
10% FBS (Sigma). For overexpression studies easy-to-
transfect human lung osteosarcoma (U2OS) and human 
embryonic kidney (HEK293) cells were also obtained 
from ATCC and cultured in DMEM medium with 10% 
FBS. Human lung adenocarcinoma (NCI-H441 and A549) 
cells were cultured in RPMI-1640 medium supplemented 
with 10% FBS. Rabbit polyclonal TTP antibodies were 
purchased from Abcam Inc. (ab36558 and ab83579). 
Mouse monoclonal anti-DDK antibody was purchased 
from Origene (Rockville, MD), and antibodies against 
β-TrCP1 and GAPDH were purchased from Cell Signaling 
Technology (Danvers, MA). Control (Cat. No. D-001810) 
and β-TrCP1 (Cat. No. D-003463) siRNA were purchased 
from Thermo Fisher Scientific (Lafayette, CO). P38 kinase 
inhibitor SB203580 (Cat. V1161) was purchased from 
Promega Corp. (Madison, WI).
Constructs
PCMV-hTTP (wild type) construct was purchased 
from Origene Inc. and was further modified to in-frame 
fused FLAG-tag. To generate serine-to-alanine mutants 
(SA) of TTP [S34A, S34/35/39A (3SA) and S186A] wild-
type construct was subjected to site-directed mutagenesis 
using the QuikChange II site-directed mutagenesis kit 
(Agilent Technologies, Santa Clara, CA).
siRNA transfection
Cells were transfected using Lipofectamine 
RNAiMAX (Invitrogen) with 20 nM of either a control 
siRNA duplex or a siRNA duplex targeting β-TrCP1 
using the protocol as described previously [43]. Twenty-
four hours after the second transfection, cells were either 
sham radiated or irradiated with 4 Gy (Philips RT250 
orthovoltage unit that produces 250 kV X-rays, Kimtron 
Inc., Oxford, CT), and the cell lysates were harvested and 
subjected to immunoblotting.
Clonogenic survival assay
Clonogenic cell survival assays were performed as 
described previously [44]. Briefly, cells (either MH-S or 
NCI-H441) were plated in triplicate at a pre-determined 
cell density. Cells were then incubated overnight under 
normal culture condition and pretreated with p38 
inhibitor (SB203580) one hour prior to different doses 
of radiation. Cells were then left for six to nine days for 
colony formation and were fixed (methanol and acetic 
acid 7:1) and stained using crystal violet solution (0.5% 
w/v). Surviving fraction following each radiation dose 
was normalized to sham-irradiated control cells and cell 
survival enhancement ratio (ER) was calculated as the 
ratio of the mean inactivation dose in the control divided 
by the irradiated cells.
Mouse lung irradiation, BAL and tissue 
collection
A breeding pair of Ttp +/- mice was obtained from 
Dr. Perry Blackshear’s laboratory and intercrossed and 
genotyped to obtain Ttp-/- mice. Both the wild-type and 
mutant mice were maintained in a C57BL/6 background. 
Male mice 6 to 8 weeks of age were either sham irradiated 
or irradiated with a single dose of 15 Gy to the whole 
lung as described previously [9]. Bronchoalveolar lavage 
(BAL) was collected using PBS containing 1% FBS and 
the recovered fluids were centrifuged (400×g for 5 min at 
4°C) and supernatants were stored at -80°C for ELISA. 
For tissue collection, the right ventricle of the heart was 
perfused with PBS to clear blood from the lungs which 
were then fixed in 10% buffered formalin. Samples were 
collected at different time points post-irradiation and 
subjected to histopathological analyses for pneumonitis.
Mouse TNF-α ELISA
TNF-α secreted into the culture medium was 
quantified using an ELISA kit (R&D systems) according 
to the manufacturer’s instructions.
Protein analyses
For immunoblotting, cell lysates were prepared as 
described previously [45]. In brief, culture dishes were 
placed on ice and washed once with ice-cold PBS. The 
required amounts of lysis buffer were added to each 
plate, and cells were harvested by scraping. Cells were 
lysed using a cup-type sonicator followed by clearing of 
debris by centrifugation at 4°C. Protein concentration 
was quantified using Bradford reagents according to 
manufacturer’s instructions.
To isolate proteins from OCT-fixed frozen lung 
sections, protocols were followed as described previously 
[46] with modifications. Briefly, OCT was dissolved by 
washing sections using PBS, followed by addition of 2X 
laemmli buffer with 2-marcaptoethanol. Samples were 
then sonicated and boiled for 10 minutes.
Mass spectrometry
Mass spectrometry analyses of TTP protein to 
identify residues phosphorylated upon irradiation were 
performed as described previously. In brief, U2OS cells 
overexpressing FLAG-tagged wild-type TTP protein were 
either sham-irradiated or exposed to 4 Gy. Thirty (30) min 
post-irradiation, cell lysates were prepared and subjected 
to immunoprecipitation. Immuno-adsorbed proteins were 
then separated on a polyacrylamide gel, and proteins were 
visualized with colloidal coomassie stain. In-gel digestion 
followed by identification of phosphorylation site mapping 
was carried out essentially as described previously [47]. 
Briefly, upon trypsin digestion,peptides were resolved on 
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a nano-capillary reverse phase column and subjected to 
high-resolution, linear ion-trap mass spectrometer (LTQ 
Orbitrap XL, Thermo Fisher). The full MS scan was 
collected in Orbitrap (resolution 30,000@400 m/z), and 
data-dependent MS/MS spectra on the nine most intense 
ions from each full MS scan were acquired. Proteins and 
peptides were identified by searching the data against the 
SwissProt human protein database, appended with decoy 
(reverse) sequences, using the X!Tandem/Trans-Proteomic 
Pipeline (TPP) software suite. All proteins identified with 
a ProteinProphet probability of >0.9 (for <1%) were 
accepted. Spectral matches to phosphorylated peptides 
were manually verified.
Statistical analysis
Data are expressed as mean ± SE. The unpaired 
Student’s t-test was used to compare the differences 
between two groups, and a P value of <0.05 was 
considered as significant.
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